KBD051 / KangBaiDa Biotechnology, Chengdu Baiyu Pharma - LARVOL DELTA

KBD051, a Novel and Highly Selective Oral TLR7/8 Antagonist, Demonstrates Prolonged Pharmacodynamic Activity and Profound Efficacy in Preclinical Models of Systemic Lupus Erythematosus (ACR Convergence 2026) - " The in vitro potency and selectivity of KBD051 were evaluated via TLR7/8/9 reporter assays, using M5049 as a control, alongside a 90-target safety panel at 10 mM. KBD051 is a highly potent and selective oral TLR7/8 antagonist that effectively blocks downstream IFN-α and IL-6 production. Notably, it demonstrates prolonged in vivo pharmacodynamic activity and profound therapeutic efficacy in the BXSB/MpJ SLE model. Supported by a favorable pharmacokinetic profile, low risk of drug-drug interactions, moderate-to-high oral bioavailability, and a wide safety margin, KBD051 has advanced into Phase 1 clinical trials as a highly promising next-generation therapeutic for SLE."

PK/PD data • Preclinical • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • IFNA1 • IL6 • TLR8 • TLR9